The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety of nivolumab/pembrolizumab in hepatitis B surface antigen-positive non-small cell lung cancer (NSCLC) patients.
 
Chongrui Xu
Honoraria - AstraZeneca; Boehringer Ingelheim; Lilly; MSD; Novartis; Pfizer; Roche
Consulting or Advisory Role - Boehringer Ingelheim; Pfizer
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD; Novartis; Pfizer; Roche
 
Hai-Yan Tu
No Relationships to Disclose
 
Yue-Li Sun
No Relationships to Disclose
 
Yang-Si Li
No Relationships to Disclose
 
Bing-Fei Xu
No Relationships to Disclose
 
Bin-Chao Wang
No Relationships to Disclose
 
Hua-Jun Chen
No Relationships to Disclose
 
Zhen Wang
No Relationships to Disclose
 
Qing Zhou
Honoraria - AstraZeneca; Roche
 
Jin-Ji Yang
No Relationships to Disclose
 
Yi-Long Wu
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD Oncology; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Roche
Research Funding - Boehringer Ingelheim (Inst); Pfizer (Inst); Roche (Inst)